Galacto-oligosaccharides

Infant formula wet-mixing lines dose the liquid galacto-oligosaccharide stream at 75 °Bx after the two-stage high-pressure homogeniser and before the plate heat exchanger, because pre-homogenization dosing changes the oil-protein interface and post-heating dosing without sterile filtration creates recontamination risk. Under Commission Delegated Regulation (EU) 2016/127, GOS and fructo-oligosaccharides are permitted only in a 9:1 ratio and at a maximum total concentration of 0.8 g/100 mL in ready-to-feed infant formula; this translates to approximately 3.0–5.9 g/100 g powder when reconstitution at 13.5 g/100 mL is used, though scoop displacement density must be verified against final blend bulk density. In direct wet-mix processing, the base formula is hydrated at 55–60 °C, emulsified, homogenised at 160–200 bar first stage and 30–50 bar second stage, then heat treated at 85–92 °C for 15–30 s before evaporation and spray drying; the reducing galactose and lactose fractions in GOS syrup can accelerate Maillard loss of lysine if liquid hold time exceeds 30 min at 60–70 °C, so production lines are flushed or the GOS dosing point is shifted immediately upstream of the dryer feed tank. Spray-drying inlet temperatures are typically 180–210 °C with outlet 85–92 °C; outlet temperatures above 95 °C or exhaust relative humidity above 55% increase amorphous powder stickiness, fouling of cyclone walls, and batch-to-batch bulk density drift in the finished can. Dry-blending operations add spray-dried GOS powder with a mean particle size of 100–250 µm to a ribbon blender or plow mixer after premixing with lactose or maltodextrin at a dilution ratio of 1:10; blend uniformity tested by near-infrared or HPAEC-PAD should achieve a coefficient of variation below 5%. Export batches destined for the United States are manufactured under 21 CFR Part 106 quality control procedures and 21 CFR Part 107 labelling provisions, though GOS itself is addressed through a firm-specific GRAS determination rather than a numeric Code of Federal Regulations concentration limit. Terminal product forms include standard first-stage infant formula, follow-on formula, ready-to-feed liquid formula, lactose-reduced formula, and specialised underweight-prevention formulas, with chlorine-free packaging and headspace nitrogen flushing required for powder products.

How Does Pre-Pasteurization GOS Dosing Change Set Yogurt Syneresis and Starter Acidification?

In fermented dairy bases, GOS syrup at 60–75 °Bx is generally dosed into the standardised milk before the upstream plate heat exchanger, because post-fermentation dosing into the white mass can be done only with cold-sanitized syrup and a post-pasteurization mixing loop that is difficult to validate on open vat lines. Fermented milks are covered by Codex STAN 243-2003, and starter culture enumeration follows ISO 7889/IDF 117; the standard does not assign a numerical GOS limit, but process authorities in dairy plants restrict GOS to 0.5–2.0 g/100 g of the dairy base to keep fermentation time and gel firmness within control limits. At addition above 2.0 g/100 g, the osmotic pressure of the milk base rises and the gel network becomes visibly softer, free whey separation increases, and the time from inoculation to pH 4.55 at 42–43 °C may extend by 12–20 min, which shifts downstream cooling and packaging schedules. The syrup selected for fermented milk should contain less than 10 g glucose/100 g dry matter; residual glucose and galactose are fermented by Streptococcus salivarius subsp. thermophilus and Lactobacillus delbrueckii subsp. bulgaricus, while the transgalactosidic DP2–DP8 fraction remains intact and contributes to post-fermentation dry matter without starter cell mass increase. In stirred yogurt, the base is pasteurised at 90–95 °C for 5–10 min, homogenised at 150–200 bar, cooled, inoculated, fermented to pH 4.55–4.60, and then cooled through a tubular heat exchanger to 20–25 °C before fruit preparation addition. Greek-style strained varieties present a different mass balance: GOS dosed before separation partitions into acid whey, so retention in the finished high-protein matrix is low; in these lines GOS is injected after centrifugal or membrane straining at the cream re-blending step, with a static mixer positioned before the packaging line. Terminal formats include set yogurt cups, stirred yogurt, drinking yogurt, high-protein strained yogurt, and probiotic co-fermented variants, but probiotic viability is measured separately by flow cytometry or plate count and is not inferable from GOS content.

When GOS Syrup Is Aseptically Injected After UHT for Enteral Formula

Enteral nutrition lines designed for sterilized liquid feed operate under Commission Delegated Regulation (EU) 2016/128 for foods for special medical purposes and Codex STAN 180-1991; product release requires osmolality, sterility, and nutrient tolerance documentation, not simply an ingredient specification. A typical adult enteral formulation uses GOS at 2.0–8.0 g/L in the final aseptically filled product; the upper boundary is determined less by hydrolysis than by gastrointestinal tolerance and by osmolality targets, with finished enteral products usually held at 300–700 mOsm/kg. Direct UHT processing at 140–145 °C for 4–10 s can produce measurable hydrolysis of GOS to galactose and glucose if the syrup is mixed before the sterilizer, especially in low-protein formulas with pH 6.2–6.8; therefore aseptic injection after the final heater and before the aseptic filler is the preferred route. The injection skid typically includes a 0.2 µm polyethersulfone membrane, a positive displacement pump with mass-flow feedback, a double-block-and-bleed valve train, and a static mixer positioned at least 2 m upstream of the filler bowl to achieve homogeneous distribution without foam. Prewarming the syrup to 40 °C reduces viscosity and increases sterile filter throughput, but exposure to sustained temperatures above 60 °C in the recirculation loop will darken the syrup and reduce transgalactosidic content. Batch failures in enteral lines are usually traceable to post-sterilisation pressure drops across the sterile filter, to pump cavitation in high-viscosity syrup, or to insufficient flushing that leaves residual carbohydrate in the aseptic valve block during prolonged shutdowns. The finished products include ready-to-hang enteral tubes, oral liquid medical nutrition, post-operative immunonutrition drinks, and diabetes-specific tube feeds; all are filled under inert gas where headspace oxygen control below 1.0% is required.

For bakery-side use of GOS, no dedicated Codex standard governs the ingredient, but the general labelling provisions of Codex STAN 1-1985 and, where fibre claims are made, Codex CAC/GL 23-1997 apply; in-process water activity is usually specified at 0.90–0.94 for soft crumb products to prevent mould while retaining pliability, with measurement by ISO 21807:2004. On flour basis, GOS is incorporated at 2.0–8.0 g/100 g; the lower range provides labelable oligosaccharide addition without marked handling changes, while the upper range increases dough stickiness, reduces mixing tolerance, and requires higher shortening or emulsifier input to maintain gas cell stability. In a typical pan bread line, GOS powder is preblended with flour and salt before being charged to a spiral mixer; water addition is adjusted by an additional 1.0–2.5% of flour weight because GOS competes for free water. Dough is mixed to a final temperature of 24–26 °C, rested, divided, rounded, and proofed at 35–38 °C and 80–85% relative humidity before entering a tunnel oven with zone temperatures of 180–220 °C. The crumb core reaches 96–100 °C during baking, conditions under which transgalactosidic bonds remain largely intact; however, in the crust, surface temperatures above 150 °C and water activity below 0.6 promote partial hydrolysis and reducing sugar accumulation, which contributes to darkening and aroma generation. Recovery of intact GOS in the crumb is routinely expected, but published data for heat-stable quantification across wheat, rye, and oat matrices remains limited; any label claim must be based on finished-product analysis by HPAEC-PAD, not on dough-side addition. Oil- or fat-rich bakery systems such as brioche and cake show reduced water activity and crumb firming when GOS replaces 3–5% of sucrose, but the resulting batter viscosity changes require in-line viscometers to be re-calibrated. Terminal product classes include sliced pan bread, high-fibre snack bars, breakfast biscuits, brioche-style enriched dough, and extruded cereal crisps; extruder barrel profiles with a final zone above 160 °C should not be used with dry GOS powder unless a preconditioner reduces moisture loss.

pH-Dependent Hydrolysis Limits Shelf-Stable Beverage Formulation Below 3.2

Still and carbonated functional beverages require a post-thermal addition window for GOS at 2.5–12.5 g/L, because the transgalactosidic bond is increasingly labile below pH 3.2 and the reaction rate increases with each 10 °C increment above 80 °C. General food safety compliance is under 21 CFR Part 117 for US-supplied finished packs and Regulation (EC) No 852/2004 for EU production; GOS is classified as a food ingredient and is not assigned an E-number under Regulation (EC) No 1333/2008, so it cannot be labelled as a food additive. The syrup or powder is dissolved in demineralised water at 25–30 °C using a high-shear mixer at 1,200–1,500 rpm, and the concentrate is then heat-pasteurised separately if a cold-fill operation is used. In hot-fill beverage lines with a filling temperature of 85–92 °C, GOS added upstream of the plate pasteuriser for a holding time of 15–45 s yields an increase in free galactose and glucose in finished beverage; this increases osmolality, accelerates non-enzymatic browning during warehouse storage at 30–35 °C, and reduces the labelled GOS content. The preferred configuration is aseptic dosing of sterile-filtered syrup into cooled beverage after the pasteurizer and before carbonation or filling; the addition point is installed with a static mixer at the filler inlet, and the line is purged with nitrogen if headspace oxygen control below 0.5 mg/L is specified. Beverage plants using flash pasteurisation at 105–110 °C for 3–5 s for juice-based drinks experience less hydrolysis than hot-fill lines, but still benefit from downstream dosing because the pH after acidification is often 3.4–3.8. Terminal products include still functional waters, juice-based prebiotic drinks, clear sports beverages, and carbonated functional beverages; addition above 10 g/L in clear beverages can produce haze and requires filtration or a final clarification step.

Compression, Moisture Pickup, and Fill-Weight Control in GOS Powder Sachets

Under cGMP conditions specified in 21 CFR Part 111, dietary supplement manufacturing with GOS powder requires batch records showing blend uniformity, microbial limits, and shelf-life water activity; EU-bound products follow Directive 2002/46/EC for food supplements, while GOS itself is a food ingredient and permitted under general food law. Adult serving sizes are typically 1.5–5.0 g GOS per day, while children-focused gummy or stick formats are formulated at 0.5–1.5 g per serving; the upper serving limit is constrained by transient gastrointestinal intolerance, not by manufacturing stability. In powder sachets, GOS is blended in a V-blender or bin blender at 60–70% fill volume for 15–20 min with anticaking agents such as silicon dioxide at 1.0–2.0% and, where tableting is required, with magnesium stearate at 0.5–1.0%; high-humidity processing above 40–45% RH is a known batch failure cause because the amorphous GOS powder adsorbs moisture, raises water activity above 0.45, and forms hard lumps that blind auger fillers and cause fill-weight drift outside ±3%. Dry granulation via roller compaction at 50–80 bar is preferred over wet granulation when improving flow and compressibility is necessary, because the carbohydrate substrate is hygroscopic and can undergo partial dissolution during wet granulation, producing particle size non-uniformity after drying. Tableting operations encounter a compressibility threshold: GOS at a concentration above 30% of the tablet core may cause sticking and edge chipping unless the press turret speed is reduced and punch lubrication is monitored by ejected tablet ejection force sensors. Finished stick packs are spot-checked for weight variation under USP <2091>. For pectin-based gummies, GOS syrup is dosed after the pectin solution has been cooked and cooled to 85 °C, and the acidulant is added only after GOS dispersion to localise pH reduction and minimise acid hydrolysis. Terminal product forms include stick sachets, capsules, pectin gummies, chewable tablets, and effervescent tablets; effervescent formats require anhydrous GOS powder and a desiccant-sealed primary pack to maintain dissolution performance.